All In Biotech

Drug Trial Radar · NCT00234832

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event

Last checked: Nov 20, 2026Latest source record: May 11, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 10,777 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,777

Actual

Start

Jan 2003

Primary completion

Mar 2009

Study completion Nov 2009

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Oct 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.

Conditions

  • Obesity

Interventions

  • Sibutramine hydrochlorideDrug

    One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)

  • PlaceboDrug

    1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)

  • Sibutramine hydrochlorideDrug

    10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)Time frame: From randomization up to 6 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Global Medical Services

    North Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.